MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Theravance Biopharma Inc. (NASDAQ:TBPH)
Organization & Developments: Theravance
Parents
Theravance Biopharma Inc. (NASDAQ:TBPH)
Children
*Glaxo is developing Relovair as a successor to its best- selling product, the Advair asthma inhaler.
*Theravance Biopharma (TBPH) is a biopharmaceutical company focused on therapeutic areas such as infectious, respiratory, gastrointestinal, cardiovascular, renal, inflammation and immunology diseases.
*U.S. drugmaker that’s helping to develop the Relovair asthma treatment
2017: Theravance Biopharma: A High Risk-Reward Investment Opportunity - Theravance Biopharma, Inc. (NASDAQ:TBPH)
2018: An Updated View On Theravance Biopharma_seekingalpha.com
2018: J&J antes up on a $1B gamble that Theravance has the next blockbuster JAK for Crohn’s, ulcerative colitis – Endpoints News
2018: The company is awaiting a major FDA approval in COPD indication in November 2018
2018: Theravance Biopharma Is A Promising Buy Opportunity In 2018 - Theravance Biopharma, Inc. (NASDAQ:TBPH)
2018: Theravance Biopharma: Johnson & Johnson Deal Looks Solid - Theravance Biopharma, Inc. (NASDAQ:TBPH)
2018: Theravance Biopharma: Prognosis Oversold_seekingalpha.com
2019: Revisiting Theravance Biopharma_seekingalpha.com
2020: Theravance Biopharma Is A Buy
2021: Circling Back On Theravance Biopharma
2022: Theravance Biopharma, Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Theravance: All-Round Failure_seekingalpha.com
2023: Theravance Biopharma: Activist Pressure Might Lead To Substantial Capital Return_ seekingalpha.com
2024: Theravance Biopharma, Inc. 2023 Q4 - Results - Earnings Call Presentation
2025: Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive
2026: Theravance halves headcount, ends all R&D work after phase 3 rare disease fail
Jumps
*Key People: Theravance
Finance & Acquisitions: Theravance